In a report released today, Matt Miksic from Credit Suisse maintained a Buy rating on Johnson & Johnson (JNJ), with a price target of $156. The company’s shares opened today at $132.50.
According to TipRanks.com, Miksic is a 5-star analyst with an average return of 16.6% and a 78.2% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Stryker Corporation, and Alcon Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Johnson & Johnson with a $150.50 average price target.
See today’s analyst top recommended stocks >>
Johnson & Johnson’s market cap is currently $357.7B and has a P/E ratio of 21.96. The company has a Price to Book ratio of 5.97.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of JNJ in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
